Stock Markets July 24, 2026 12:25 PM

Vir Biotechnology Shares Slip After CFO Jason O’Byrne Announces Departure

Brent Sabatini named interim finance chief as company begins search for permanent successor

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
VIR AMGN

Vir Biotechnology Inc. shares declined following the company’s announcement that Chief Financial Officer Jason O’Byrne will leave to pursue another opportunity. Brent Sabatini, the company’s Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer effective July 23 while the company searches for a permanent replacement.

Vir Biotechnology Shares Slip After CFO Jason O’Byrne Announces Departure
VIR AMGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Vir Biotechnology shares declined 5.6% after the company announced CFO Jason O’Byrne will leave to pursue another opportunity; O’Byrne will remain through August 3.
  • Brent Sabatini, Senior Vice President and Chief Accounting Officer since February 2023, will serve as Interim Principal Financial Officer effective July 23 while the company conducts a search for a permanent CFO.
  • Sabatini brings over two decades of experience, including prior roles as Head of Finance at Capsida Biotherapeutics and leadership positions at Amgen; he is a CPA with degrees from CSU Northridge and the University of Michigan.

Shares of Vir Biotechnology Inc (NASDAQ:VIR) fell 5.6% on Friday after management disclosed that Chief Financial Officer Jason O’Byrne will depart the company to pursue another opportunity. The firm said O’Byrne will remain with Vir through August 3 to support the handover to his successor.

Effective July 23, Brent Sabatini, who currently serves as Senior Vice President and Chief Accounting Officer, will assume the role of Interim Principal Financial Officer. The company has started a search for a permanent CFO.

Sabatini has been Vir’s Senior Vice President and Chief Accounting Officer since February 2023. The company noted his more than two decades of experience in finance and accounting, including a role as Head of Finance at Capsida Biotherapeutics, Inc. Before that, Sabatini worked at Amgen Inc (NASDAQ:AMGN) from 2004 to 2021, where he held leadership positions across Accounting, Tax and Financial Planning and Analysis.

"Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish a strong cash position for the Company," said Marianne De Backer, Chief Executive Officer of Vir Biotechnology.

Sabatini is a Certified Public Accountant and holds a B.S. in Accountancy from California State University, Northridge, as well as an MBA from the University of Michigan’s Stephen M. Ross School of Business.

Vir Biotechnology is described by the company as a clinical-stage biopharmaceutical enterprise focused on discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs targeting chronic hepatitis delta and several PRO-XTEN dual-masked T-cell engagers aimed at validated targets in solid tumor indications.

The company’s announcement of the CFO transition and the appointment of an interim finance leader comes as Vir continues its clinical development activities and seeks to maintain financial continuity during the search for a permanent chief financial officer.

Risks

  • Leadership transition risk: The departure of a CFO and an ongoing search for a permanent replacement could create short-term uncertainty in financial leadership at Vir, impacting investor sentiment and financial planning.
  • Market reaction risk: The stock decline following the announcement highlights potential volatility in the company’s share price tied to executive changes.
  • Continuity of financial strategy: With an interim finance chief in place, there is uncertainty about how long it will take to identify and onboard a permanent CFO and how that may affect execution of strategic initiatives.

More from Stock Markets

Anthropic debuts Claude Opus 5 as lower-cost option for workplace AI tasks Jul 24, 2026 Blackstone, Donerail and Centerbridge Emerged as Final Bidders for MarineMax Jul 24, 2026 Surgery Partners to Sell Two Idaho Falls Hospitals in $1.15 Billion Transaction Jul 24, 2026 World Cup Demand Lifts Hotels While Middle East Tensions Cloud Outlook for Online Travel Firms Jul 24, 2026 Sidus Space Names Alan Khalili as CFO; Shares Slip After Announcement Jul 24, 2026